1992
DOI: 10.1016/0042-6822(92)90243-i
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of the specificity and genetic restriction of human CD4+ cytotoxic T cell clones reactive to capsid antigen of rubella virus

Abstract: Using 11 overlapping synthetic peptides covering more than 95% of the amino acid sequence of capsid protein of rubella virus, 7 CD4+ T cell clones (R10, R11, R18, A2, A10, A11, and A12) isolated from 2 rubella seropositive donors reacted strongly to rubella capsid peptides C6 (residues 119-152), C9 (residues 205-233), or C11 (residues 255-280), respectively, in both proliferation and cytotoxicity assay. Truncated peptides C6E (residues 125-139), C9B (residues 205-216), and C11E (residues 260-272) were shown to… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

1993
1993
2000
2000

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 15 publications
(13 citation statements)
references
References 27 publications
0
13
0
Order By: Relevance
“…The T-cell clones (ATRVC2 and AT177C5) used for this study were isolated from two CD4+CD8 T-cell lines derived from a single RVseropositive donor as described previously [22,24,25]. Briefly, PBMNCs were incubated with UV-inactivated RV (5 × 105 FFU/ml) or the SP E1(273-291), which was used at a final concentration of 15 ~g/ml in complete RPMI-1640 medium containing 2 mM L-glutamine, 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (Hepes), 50 mM penicillin, 50 mM streptomycin, and 5 × 10 -5 M 2-mercaptoethanol, which was also supplemented with 10% autologous plasma.…”
Section: Rv-specific T-cell Clonesmentioning
confidence: 99%
See 1 more Smart Citation
“…The T-cell clones (ATRVC2 and AT177C5) used for this study were isolated from two CD4+CD8 T-cell lines derived from a single RVseropositive donor as described previously [22,24,25]. Briefly, PBMNCs were incubated with UV-inactivated RV (5 × 105 FFU/ml) or the SP E1(273-291), which was used at a final concentration of 15 ~g/ml in complete RPMI-1640 medium containing 2 mM L-glutamine, 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (Hepes), 50 mM penicillin, 50 mM streptomycin, and 5 × 10 -5 M 2-mercaptoethanol, which was also supplemented with 10% autologous plasma.…”
Section: Rv-specific T-cell Clonesmentioning
confidence: 99%
“…HCLs, EBV-BLs BSM, YAR, JHa, PF, KB, HOM2, MAT, CRI, Ig-38, MST, SST, and KT2, which are homozygous at the HLA region, with different HLA-DR phenotypes or DR4 subtypes (Tables 4 and 5 Cell-mediated cytotoxicity assay. A standard 51Cr-release assay was used to measure CTL responses [22,23,25]. For use as CTL targets, EBV-BL or HCL cells (1 × 106) were sensitized by overnight incubation at 37°C with 1 × 106 FFU of UV-inactivated RV, or 5 I-~g/ml rE 1BV, or 10 gtM of SP in 1 ml of complete RPMI medium.…”
Section: Ebv-bls Hla Homozygous Ebv-bls (Hcls) With Different Hla-drmentioning
confidence: 99%
“…To examine the crossrecognition of RV antigens and beta-cell antigens by T-cells from different patient cohorts, a panel of 15 peptides (V1-V15) of RV structural protein E1, E2, and C were selected for this study (Table 2). Peptides V1, V4, V5, V8, V11, V13, V14, V15 are antigenic peptides containing epitopes identified by T-cells from RV seropositive healthy donors or RV vaccinees or both in our previous studies [32,33,43,44]. RV peptides V2, V3, V6, V7, V9, V10, V12 were shown earlier to be recognised by peripheral blood T-cells of CRS patients [31] and included five (V3, V6, V7, V9, V12) which stimulated cellular responses of a CRS patient who also had Type I diabetes.…”
Section: Resultsmentioning
confidence: 99%
“…Two kinds of EBV-BL were used as targets in 51Cr release assay. EBV-BLs AT (autologous to T-cell clone AT177C5) was established in our laboratory by the method described previously (22)(23)(24). HCLs, EBV-BLs BSM, YAR, SST, JHa, MT, KT2, and KT3, which are homozygous at the HLA region, and EBV-BL P9B, which is heterozygous at HLA-DR (DR4/DR2), with different HLA-DR phenotypes or DR4 subtypes (Table 2) were provided kindly by Dr. G.T.…”
Section: Methodsmentioning
confidence: 99%
“…A standard 51Cr release assay was used to measure CTL responses (22)(23)(24). Briefly, for use as CTL targets, EBV-BL or HCL cells (1 X 106) were incubated at 37°C with 10 pM.…”
Section: Methodsmentioning
confidence: 99%